Catalyst Pharmaceuticals, Inc.
CPRX
$24.42
$0.180.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 588.99M | 578.20M | 558.50M | 534.65M | 491.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 588.99M | 578.20M | 558.50M | 534.65M | 491.73M |
| Cost of Revenue | 99.96M | 97.52M | 94.77M | 88.19M | 81.49M |
| Gross Profit | 489.03M | 480.67M | 463.73M | 446.46M | 410.24M |
| SG&A Expenses | 193.75M | 184.52M | 182.93M | 177.71M | 177.74M |
| Depreciation & Amortization | 37.50M | 37.38M | 37.38M | 37.38M | 37.38M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 331.21M | 319.42M | 315.08M | 303.28M | 296.61M |
| Operating Income | 257.78M | 258.78M | 243.42M | 231.37M | 195.12M |
| Income Before Tax | 283.52M | 285.80M | 271.97M | 258.46M | 216.26M |
| Income Tax Expenses | 69.19M | 68.23M | 63.30M | 61.11M | 52.37M |
| Earnings from Continuing Operations | 214.33 | 217.56 | 208.67 | 197.35 | 163.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 214.33M | 217.56M | 208.67M | 197.35M | 163.89M |
| EBIT | 257.78M | 258.78M | 243.42M | 231.37M | 195.12M |
| EBITDA | 295.65M | 296.57M | 281.25M | 269.17M | 232.90M |
| EPS Basic | 1.75 | 1.79 | 1.73 | 1.65 | 1.38 |
| Normalized Basic EPS | 1.44 | 1.45 | 1.37 | 1.30 | 1.11 |
| EPS Diluted | 1.69 | 1.72 | 1.65 | 1.57 | 1.31 |
| Normalized Diluted EPS | 1.39 | 1.39 | 1.30 | 1.24 | 1.05 |
| Average Basic Shares Outstanding | 489.14M | 486.13M | 482.46M | 478.48M | 473.81M |
| Average Diluted Shares Outstanding | 509.02M | 507.87M | 506.19M | 503.30M | 499.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |